Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 101 (5), 871-4

Self-sampling of the Vaginal Fluid at Home Combined With High-Risk HPV Testing

Affiliations
Clinical Trial

Self-sampling of the Vaginal Fluid at Home Combined With High-Risk HPV Testing

K Sanner et al. Br J Cancer.

Abstract

Background: Around 65% of women with cervical carcinoma in Sweden have not attended an organised screening. We therefore investigated the value of using self-sampling at home in combination with a test for high-risk human papilloma virus (HPV) to increase participation.

Methods: A total of 2829 women 30-58 years old, who had not attended the organised screening for > or = 6 years, were recruited. They were offered self-sampling at home (Qvintip) and recommended to send the collected vaginal fluid to a laboratory for analysis of the presence of high-risk HPV (Hybrid Capture 2 method).

Results: A total of 39.1% of the women accepted home sampling. These women disclosed a relatively high prevalence of high-risk HPV, which decreased with age, from 11.1% in women 30-39 years old to 2.9% in women > or =50 years . Follow-up disclosed histological cervical intraepithelial neoplasm (CIN) 2-3 lesions in 43.2% of the women with a persistent HPV infection, corresponding to 2.0% of the total number of participating women. The sensitivity of a single smear to detect the histological CIN 2-3 lesions were only 52.6%, even if all abnormal smears (atypical squamous cells of unknown significance (ASCUS)-CIN 3)) were included.

Conclusion: The use of self-sampling at home in combination with testing for high-risk HPV increases the participation rate of the organised screening and detects almost twice as many women with pre-malignant cell alterations (CIN 2-3) in comparison those with a single cytological smear.

Figures

Figure 1
Figure 1
Illustration of the relationship between ordering a self-sampling device and the collection of the vaginal fluid at home with respect to time lapse.

Similar articles

See all similar articles

Cited by 31 PubMed Central articles

See all "Cited by" articles

References

    1. Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, Dillner J, Törnberg S. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:605–606. - PubMed
    1. Bergström R, Sparén P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 1999;81:159–166. - PMC - PubMed
    1. Bos A, Rebolj M, Habbema JD, van Ballegooijen M. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer. 2006;119:2372–2375. - PubMed
    1. Forslund O, Antonsson A, Edlund K, van der Brule AJ, Hansson BJ, Meijer CJ, Ryd W, Rylander E, Strand A, Wadell G, Dillner J, Johansson B. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol. 2002;67:535–541. - PubMed
    1. Gustafsson L, Sparén P, Gustafsson M, Pettersson B, Wilander E, Bergstrom R, Adami HO. Low efficiency of cytological screening for cancer in situ of the cervix in older women. Int J Cancer. 1995;63:804–809. - PubMed

Publication types

Feedback